Dupilumab for cancer-associated refractory pruritus

Dupilumab for cancer-associated refractory pruritus

Background: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

Description complète

Détails bibliographiques
Auteurs principaux: Aviv Talmon, MD, Shlomo Elias, MD, PhD, Limor Rubin, MD, Yaarit Ribak, MD, Eyal Ben Dori, MD, Oded Shamriz, MD, Michal Lotem, MD, Irit Adini, PhD, Yuval Tal, MD, PhD
Format: Article
Langue:English
Publié: Elsevier 2023-08-01
Collection:Journal of Allergy and Clinical Immunology: Global
Sujets:
Oncologic pruritus
chronic pruritus
itch
IL-4
IL-13
IL-31
Accès en ligne:http://www.sciencedirect.com/science/article/pii/S277282932300053X

Internet

http://www.sciencedirect.com/science/article/pii/S277282932300053X

Documents similaires